Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working ...
One unexpected symptom of depression in older adults that many often miss is fatigue. "A person who is depressed does not ...
Then one day, after I was talking about my migraine experience with family, I overheard my father-in-law ask my husband if I ...
The court appeared ready to invalidate laws in some two dozen states that bar therapists from practicing a version of therapy that seeks to change a teenager's sexual orientation or gender identity.
Have you noticed you're sleeping a little longer? Maybe you're experiencing a shift in appetite — craving more sweets or pasta. In autumn, our bodies sense the change in light as the dark winter ...
Florida Tech teams with Southern Smoke Foundation to provide help for struggling food service industry workers.
The neurodegenerative disease damages patients’ motor, cognitive and behavioral controls, which sometimes manifest as ...
22don MSN
Regulators struggle to keep up with the fast-moving and complicated landscape of AI therapy apps
As mental health chatbots driven by artificial intelligence proliferate, a small number of states are trying to regulate them. Laws in Illinois, Nevada and Utah are among the first in the nation ...
On Aug. 15 Presents announced a new, indoor concert series called “Thanks for the Memories.” The announcement came on the heels of Fridays on the Plaza, which had a record-breaking summer, with some ...
In the absence of stronger federal regulation, some states have begun regulating apps that offer AI “therapy” as more people turn to artificial intelligence for mental health advice. But the laws, all ...
The Canadian Press on MSN
Today-History-Oct20
Today in History for Oct. 20: In 1632, Sir Christopher Wren, British astronomer and architect, was born. He designed 53 London churches, including St. Paul's Cathedral, as well as several secular ...
The FDA has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adults with treatment-resistant depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results